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Treatment patterns and economic burden
of sickle-cell disease patients prescribed
hydroxyurea: a retrospective claims-based
study
Nirmish Shah1, Menaka Bhor2, Lin Xie3,4* , Rashid Halloway2, Steve Arcona2, Jincy Paulose2 and Huseyin Yuce4
Abstract
Background: This study aimed to evaluate sickle-cell disease (SCD) treatment patterns and economic burden
among patients prescribed hydroxyurea (HU) in the US, through claims data.
Methods: SCD patients with pharmacy claims for HU were selected from the Medicaid Analytic Extracts (MAX)
from January 1, 2009 - December 31, 2013. The first HU prescription during the identification period was defined as
the index date and patients were required to have had continuous medical and pharmacy benefits for ≥6 months
baseline and 12 months follow-up periods. Patient demographics, clinical characteristics, treatment patterns, health
care utilization, and costs were examined, and variables were analyzed descriptively.
Results: A total of 3999 SCD patients prescribed HU were included; the mean age was 19.24 years, most patients
were African American (73.3%), and the mean Charlson comorbidity index (CCI) score was 0.6. Asthma (20.3%),
acute chest syndrome (15.6%), and infectious and parasitic diseases (20%) were the most prevalent comorbidities.
During the 12-month follow-up period, 58.9% (N = 2357) of patients discontinued HU medication. The mean
medication possession ratio (MPR) was 0.52, and 22.3% of patients had MPR ≥80%. The average length of stay (LOS)
for SCD-related hospitalization was 13.35 days; 64% of patients had ≥1 SCD-related hospitalization. The mean
annual total SCD-related costs per patient were $27,779, mostly inpatient costs ($20,128).
Conclusions: Overall, the study showed the patients had significant unmet needs manifest as poor medication
adherence, high treatment discontinuation rates, and high economic burden.
Keywords: Hydroxyurea, Adherence, Discontinuation, Health care, Cost, Utilization
Background
Sickle-cell disease (SCD) consists of a group of rare genetic
blood disorders characterized by a single missense mutation
(Glu6Val) in the β-globin gene. The mutated hemoglobin
in SCD, known as sickle hemoglobin (HbS), is less soluble
and prone to polymerization upon deoxygenation, causing
red blood cell sickling, which contributes to numerous
other complications [1–3], as SCD progresses early on into
a systemic disease. Vaso-occlusion is the primary indicator
of SCD and can lead to serious acute and chronic
complications; vascular dysfunction, inflammation, and P-
selectin mediated cell-to-cell and cell-to-endothelium adhe-
sion play an important role in the pathophysiology of SCD
vaso-occlusive crisis (VOC), which is the most common
clinical manifestation of SCD. Every VOC increases mor-
bidity, and can result in organ damage or failure,
acute chest syndrome (ACS), stroke, end-organ dam-
age, or death [4–12]. The Centers for Disease Control
and Prevention has estimated that 100,000 Americans
are burdened with SCD, and in newborn infants it oc-
curs most frequently among African-Americans [13].
Most notably, SCD has been associated with high
physical and economic burden [14].
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Among SCD-related complications, VOC events have
long been identified as a higher risk factor for death and
the most common cause of hospital admission among
SCD patients [15]. A 5-year study carried out using Flor-
ida Medicaid program data estimated that SCD patients
had an average of 3.7 inpatient hospitalizations and 24.1
hospital days during the study period, with roughly 84%
attributable to SCD-related diagnoses [16].
Currently, treatment and prevention options for VOCs
are limited. It was not until the 1990s that the efficacy of
hydroxyurea (HU) was first demonstrated in the preven-
tion of VOCs [17]. In the US, HU was first approved by
the FDA for use in the adult SCD population in 1998,
and was recently approved for use in the pediatric SCD
population in 2017 [18]. HU affects certain cells in the
body, such as cancer cells and sickled red blood cells. It
is used to treat cancers including chronic myeloid
leukemia, ovarian cancer, and certain types of skin can-
cer such as squamous cell cancer of the head and neck.
HU is also used palliatively to reduce pain episodes and
the need for blood transfusions in people with sickle cell
anemia, although it will not cure sickle cell anemia [19].
HU’s mechanism of action (MOA) includes increasing
the concentration of fetal hemoglobin, lowering the
number of circulating leukocytes and reticulocytes, and
decreasing their expression of adhesion molecules,
thereby decreasing vascular occlusion. Other MOAs
include increasing the size of the reticulocytes and
improving cellular deformability, which increases blood
flow and reduces vaso-occlusion and its associated
complications. Furthermore, metabolism of HU releases
nitric oxide, which can cause local vasodilation [20, 21].
HU has been proven to effectively decrease the fre-
quency of pain episodes and other acute complications
in multiple randomized controlled trials [22]. Studies
have shown that HU can be used as a substitute for
chronic transfusions for the prevention of primary stroke
among high-risk SCD pediatric patients with abnormal
transcranial doppler (TCD) flow velocity [23, 24]. Also,
observational studies have shown a relationship between
HU use and decreased rates of hospitalization and blood
transfusions [25, 26]. More recently, the FDA approved
oral L-glutamine therapy for SCD patients aged 5 years
and older to reduce the number of acute complications
associated with the blood disorder [27]; while this medi-
cation’s MOA is not well understood, it is believed to re-
sult from a reduction of intracellular oxidation damage
[28]. Adverse events associated with HU include GI
symptoms such as loss of appetite, nausea, constipation
and diarrhea; other symptoms include infection and
bleeding [19].
VOCs lead to significant health care utilization and are
the most common cause of emergency room (ER) visits
and hospital admissions among SCD patients, with total
medical costs exceeding $1.1 billion in the US annually
[16]. A US study using the Healthcare Cost and Utilization
Project (HCUP) database was conducted to assess nation-
wide hospitalizations for SCD patients from 1994—2004,
and estimated the annual direct hospitalization-related
costs for SCD at $488 million [29]. Another study in 2015
estimated the average cost per patient-month at $1389,
with a lifetime cost of care of approximately $460,000 per
patient with SCD [16]. The Bou-Maroun et al. analysis in
2018 determined that annual health care expenditures for
SCD hospitalization resulted in costs over $900 million,
with a median hospitalization cost of $14,337 per stay per
patient [30]. Blinder et al. examined age-related treatment
patterns among SCD patients and the associated compli-
cations and health care costs; their results showed that
quarterly total health care costs per patient ranged from
$11,913–$11,957 among patients who received ≥10 blood
transfusions [31].
Several studies that have examined the cost-effectiveness
of HU support the advantages of HU use for clinical and
economic benefits [26]. One study observed that HU use
among pediatric patients resulted in reduced hospitalization
and decreased health care costs [32]. Notably, studies have
also shown that there is underutilization of HU among
SCD patients, considering the significant efficacy of the
drug [33]. However, few analyses have examined HU
treatment patterns among SCD patients, and none have
examined HU treatment patterns in a real-world setting.
To demonstrate real-world treatment patterns of SCD
patients prescribed HU, this study descriptively evaluated
treatment patterns and the economic burden of SCD




This was a retrospective, descriptive study of the charac-
teristics and treatment patterns of SCD patients pre-
scribed HU during the period of 01JAN2009 through
31DEC2013, using the US Medicaid population database.
The MAX data system contains extensive individual-
level information on the characteristics of Medicaid enrol-
lees in all 50 states and the District of Columbia, as well as
the services used during a calendar year. Specifically,
MAX consists of 1 personal summary file and 4 claims
files that provide fee-for-service (FFS) claims, managed
care encounter data, and premium payments. The study
included FFS patients from all available states and man-
aged care enrollees who resided in 14 states with the most
relatively complete data available: Arizona, California,
Indiana, Kansas, Kentucky, Minnesota, Nebraska, New
Jersey, New Mexico, New York, Oregon, Tennessee,
Texas, and Virginia. Service use among Managed Care
enrollees is captured in encounter data. Patients who had
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dual eligibility with Medicare were not included in this
study due to incomplete information in the MAX
database.
Patient selection
Patients were included if they had ≥1 pharmacy claim
for HU during the identification period (01JUL2009
-01DEC2012); the first observed HU claim date was des-
ignated as the index date.
Patients were also required to have continuous health
plan enrollment with medical and pharmacy benefits
during the 6 months before the index date (baseline
period) and 12 months after the index date (follow-up
period). In addition, they were required to have ≥1 diag-
nosis claim with SCD (International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM] codes: 282.41–282.42, 282.60–282.69) before the
index date. Patients were excluded from the study if they
were enrolled in a clinical trial during the study period
(identified using ICD-9-CM: V70.7).
Baseline measures
Socio-demographics and clinical characteristics were
evaluated for the baseline period including age, sex,
race/ethnicity, geographical region, and Charlson Co-
morbidity Index (CCI) score. Baseline individual comor-
bid conditions were flagged including VOCs, pulmonary
conditions (eg, ACS), cerebrovascular conditions (eg,
stroke), hepatic and biliary conditions (eg, gallstones),
splenic conditions (eg, splenic sequestration), and other
conditions that commonly occur among SCD patients.
Baseline all-cause health care resource utilization and
costs were also identified by inpatient, outpatient (ER,
office, other), and pharmacy visits. Health care costs
were calculated only for patients enrolled in an FFS Me-
dicaid plan.
Outcome measures
HU treatment patterns during the 12-month follow-up
period were examined. HU discontinuation was defined
as an observed refill gap of ≥90 days between two subse-
quent prescriptions. The period from the index date to
the discontinuation date was also examined. Sensitivity
analysis using 30- and 60-day refill gaps were also con-
ducted to measure discontinuation. Medication posses-
sion ratio (MPR) was calculated as the ratio of the total
number of days of supply of HU to the total number of
days in the follow-up period. The average daily dose was
examined; dosing modification between the average HU
daily dose during the follow-up period and on the index
date was calculated. Treatments prescribed during the
first 12 months of the follow-up period were identified.
Monitoring patterns such as laboratory and radiology
tests—in addition to all-cause and SCD-related health
care resource utilizations and costs during the 1-year
post-index date—were examined by facility type. The
rate of complicated and uncomplicated VOCs was also
examined, and health care costs were calculated only for
patients enrolled in an FFS Medicaid plan.
Statistical methods
All variables were analyzed descriptively. Percentages
and numbers were provided for dichotomous and poly-
chotomous variables. Means and standard deviations
were examined for continuous variables.
Results
Baseline characteristics for the SCD patients prescribed
HU
A total of 3999 eligible patients met the study selection
criteria and were included for analysis (Fig. 1). The mean
age was 19.24 years (standard deviation [SD] = 11.85).
Approximately half the study population (51.8%) were
aged under 18 years, and the majority (73.3%) of SCD
patients were African-American. The remaining 26.7%
were comprised of whites, Hispanics, and patients of
other or unspecified ethnicity. In addition, the mean
CCI score was 0.60 (Table 1).
More than half of the study population (53.6%) had a
VOC during the baseline period. Pulmonary conditions
such as asthma (20.3%), ACS (15.6%), and upper respira-
tory tract infections (11.6%) were the most prevalent co-
morbid conditions. Other frequent conditions observed
among the study population included fever (31.4%), in-
fectious and parasitic diseases (20.0%), and constipation
(12.1%, Table 1).
Baseline health care utilization
During the 6-month baseline period, all-cause health
care utilization results showed that 90.0% had ≥1 out-
patient hospital visit, 78.4% had ≥1 outpatient office visit,
71.1% had ≥1 outpatient ER visit, and 60.3% had ≥1 in-
patient visit. The average length of stay (LOS) was 9
days, with a mean number of inpatient stays of 1.75 and
3.20 for outpatient ER visits (Fig. 2).
Baseline health care costs
Mean total costs for all-cause health care during the 6-
month baseline period were $19,194; the primary cost
drivers were inpatient ($12,806); pharmacy ($2371); out-
patient ($3563); and ER costs ($406); other costs includ-
ing laboratory visits and ambulatory costs amounted to
$48.
Follow-up results
Treatment patterns for SCD patients prescribed HU
Treatment patterns during the 12-month follow-up period
were measured. Using a 90-day treatment gap to define
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discontinuation, the rate of HU discontinuation was 58.9%
(N = 2357). The average time-to-discontinuation was 202
days, with and < 50% of the SCD patients remaining on
HU after 200 days (Fig. 3). During the 1-year follow-up
period, 52.5% of the 2357 patients reinitiated HU. Using a
30-day gap to define discontinuation, the rate of HU dis-
continuation was 87.8% (N = 3512), and 76.7% (N = 2692)
reinitiated HU. With a 60-day gap, 72% (N = 2878) of pa-
tients discontinued HU, and 65% (N = 1870) reinitiated
HU (Additional file 1: Table S1).
The mean MPR was 0.52 (SD = 0.36) among the over-
all HU patients; less than half (48.7%) of the study popu-
lation had MPR ≥50%, and less than one-quarter (22.3%)
of patients had MPR ≥80% (Fig. 4).
The average index dose of HU was 980.6 mg with an
average decrease of 3.9 mg during the follow-up period.
Other concomitant medications used after the index
date included antibiotics (77.6%), folic acid (75.1%), and
opioids (49%; Fig. 5). Nearly 38.1% of the population had
≥1 episode of blood transfusion with an average of 1.11
Fig. 1 Flow chart for patient selection criteria. HU: hydroxyurea; SCD:
sickle cell disease
Table 1 Baseline demographic and clinical characteristics of
SCD patients prescribed HU
Patient characteristics Sickle cell patients prescribed HU
(N = 3999)
N/Mean %/SD
Age (years) 19.24 11.85
Age Group


















North Central 590 14.8%
South 1501 37.5%
West 573 14.3%





Individual Comorbid Conditions (≥5%)
Fever 1255 31.4%
Asthma 811 20.3%
Infectious and parasitic diseases 798 20.0%
Acute chest syndrome 623 15.6%
Constipation 485 12.1%
Upper respiratory tract infections 462 11.6%
Aseptic (avascular) bone necrosis 307 7.7%
Iron overload 298 7.5%
Gallstones 214 5.4%
Chronic pain 205 5.1%
Neoplasms benign and malignant 198 5.0%
Sepsis 198 5.0%
HU hydroxyurea, SCD sickle cell disease, SD standard deviation
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blood transfusions during the follow-up period; 25.0%
were administered transcranial doppler ultrasonography.
Only 4.4% of the population had pneumococcal vaccine,
2.9% had meningococcal vaccine, and 0.3% of the pa-
tients received a bone marrow transplant during the 12-
month follow-up period (Table 2).
Monitoring patterns
A majority (73.6%) of the patients had a complete blood
count performed, 69.6% had a chest x-ray, 36.1% had an
electrocardiogram, 31% had echocardiography, 29.2%
had serum iron studies done, and 21% had an x-ray of
an extremity carried out during the follow-up period.
Other tests carried out included eye examination
(22.7%), plain abdominal x-ray (14.7%), and computer-
ized tomography (CT) scan (8.5%) during the follow-up
period (Table 2). Approximately 99.1% of the patients
who had a VOC presented with a form of complication,
and 10.13% of the patients had ACS during the follow-
up period.
Health care resource utilization
All-cause health care resource utilization results showed
65.2% of patients had ≥1 inpatient visit during the
follow-up period. The average number of inpatient visits
was 2.83, with a mean LOS of 14.69 days. In addition,
78.3% of the patients had ≥1 ER visit with a mean of
6.20 visits and a median of 3 visits. Also, 94.5% had ≥1
outpatient hospital visit (mean: 13.63 visits; median: 9
visits). About 86.5% had ≥1 outpatient office visit (mean:
8.06 visits; median: 5 visits) during the 12-month follow-
up period (Fig. 6).
The mean LOS for inpatient stays was 13.35 days for
SCD-related hospitalization. Furthermore, 64% of the
Fig. 2 Baseline all-cause health care resource utilization. ER: emergency room
Fig. 3 Kaplan Meier curve for time to HU discontinuation. HU: hydroxyurea
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patients had ≥1 SCD-related hospitalization and the
mean number of visits was 2.5. About 67.3% of the pa-
tients had ≥1 SCD-related outpatient ER visit, with a
mean number of 4.71 visits and median of 2 visits.
About 64.3% of the patients had ≥1 outpatient office
visit with a mean of 3.86 and median of 2 visits. Also,
89.8% of patients had ≥1 SCD-related outpatient hospital
visit, with a mean of 9.97 visits and median of 7 visits
during the 12-month follow-up period (Fig. 6).
Health care costs
Mean total all-cause health care costs during the 12-
month follow-up period were $36,253 and the majority
were due to inpatient costs ($23,000). In addition, phar-
macy costs were $5038, outpatient costs were $7417, ER
costs were $758, and other costs including laboratory
visit and ambulatory costs, amounted to $40. SCD-
related health care costs during the 12-month follow-up
period were $27,779 (mean total costs), and the main
cost driver was inpatient costs ($20,128). Pharmacy costs
were $4656, outpatient costs were $2399, ER costs were
$579, other costs, which included laboratory visits and
ambulatory costs, amounted to $18 (Fig. 7).
Discussion
This study provides real-world evidence of the demo-
graphic and clinical characteristics, treatment patterns,
and economic burden of adult and pediatric SCD pa-
tients who were prescribed HU treatment. Although HU
was only recently approved for pediatric use (December
2017), the results of this study showed that nearly half
the study population of patients prescribed HU were
aged under 18 years.
Although studies have shown that continuing regular
HU treatment decreases or prevents complications of
SCD [34], our study showed poor adherence to HU
treatment. Specifically, findings included a mean MPR of
0.52, less than half of the study population had an MPR
≥50%, and less than one-quarter of patients had an MPR
≥80%. The results are similar to the findings in another
study that observed low HU adherence, in which 38% of
SCD patients with HU treatment had an MPR ≥80%
[35]. In addition, defining HU discontinuation using a
30- to 90-day prescription gap between two subsequent
prescriptions, the rate of HU discontinuation ranged
from 58.9 to 87.8%, and 52.5 to 76.7%, among those who
reinitiated HU. Specific reasons for discontinuation or
poor HU adherence could not be ascertained in this
study. However, a previous study carried out among
younger SCD patients (aged 12–18 years) showed that
half the participants had low HU adherence, and that
patients who were more concerned about HU-related
adverse events were more likely to report lower HU ad-
herence [36]. Other studies have shown that, in addition
to concerns such as HU-related adverse events, the costs
and inconvenience associated with monitoring required
during HU therapy as well as recall barriers and forget-
fulness may contribute to the low HU compliance ob-
served in most patients [33, 37, 38]. Furthermore,
Fig. 4 MPR for SCD patients during the 12-month follow-up period.
MPR: mean possession ratio
Fig. 5 Concomitant SCD treatments during the follow-up period. SCD: sickle cell disease; NSAIDs: non-steroidal anti-inflammatory drugs
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Table 2 Treatment patterns of SCD patients prescribed HU




HU index dose (mg) 980.63 656.62
Dosing modification −3.85 468.16
SCD Management (during the first 12 months)
Blood transfusions
# of Patients 1523 38.1%
Number of blood transfusions 1.11 2.28
Transcranial Doppler ultrasonography 1001 25.0%
Pneumococcal vaccine 175 4.4%
Meningococcal vaccine 115 2.9%
Bone marrow transplant 11 0.3%
Monitoring Patterns (during a 12-month period)
Chest X-ray 2784 69.6%
X-ray of extremity 839 21.0%
Abdominal plain film 586 14.7%
Computerized tomography 341 8.5%
Nuclear medicine studies 158 4.0%
Echocardiography 1239 31.0%
Electrocardiogram 1444 36.1%
Eye exams 909 22.7%
Complete blood count 2945 73.6%
Iron tests 1167 29.2%
SCD sickle cell disease, HU hydroxyurea, SD standard deviation
Fig. 6 Proportion of patients with numbers of visits for all-cause and SCD-related health care utilization. SCD: sickle cell disease; ER:
emergency room
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Badawy et al. showed that patients’ concerns about po-
tential adverse events associated with HU, and concerns
about overuse of HU medication in general, were associ-
ated with worse health-related quality of life [36]. A sur-
vey study of over 200 pediatric hematologists managing
SCD patients revealed that the most common factors
identified as barriers to HU use involved compliance.
Most health care providers acknowledged that concerns
with low HU compliance were low laboratory monitor-
ing compliance, and low contraception compliance
among female patients [39]. Furthermore, over 99% of
the SCD patients in this study had a form of complica-
tion associated with VOC, and the rate of ACS among
study patients was 10.13%. Although few studies have
examined the rate of ACS in SCD patients, to our know-
ledge, no other study has examined the rate of ACS
among SCD patients who were prescribed HU.
In addition to HU adherence, our study also examined
monitoring patterns of SCD patients with HU use. The
HU treatment guidelines for SCD patients recommend
monitoring at least every 8–12 weeks. Evidence suggests
that SCD patients treated with HU who received fre-
quent monitoring had improved medication adherence
and clinical outcomes [40]. A study showed monitoring
of SCD patients on HU occurred every 4–6 weeks during
escalation of therapy and every 8–12 weeks upon
achievement of maximal tolerated dose (MTD). Moni-
toring included a physical examination, patient’s history,
and laboratory testing. The most commonly ordered la-
boratory tests used to monitor SCD patients on HU
were complete blood counts, although liver function
tests, renal function tests, and reticulocyte count are also
frequently monitored [41]. However, this study’s results
showed that only 73.6% of SCD patients prescribed HU
had ≥1 complete blood count test post-HU initiation,
27.2% of the patients had ≥1 serum iron study done, and
the mean number of laboratory visits was 1.3 during the
12-month follow-up period.
This study also observed a high rate of morbidity asso-
ciated with SCD, as a large proportion of all-cause hos-
pitalizations (98.4%), LOS (90.9%) and ER admissions
(86%) were attributed to SCD. An ad hoc analysis carried
out assessing Medicare SCD patients with or without a
history of HU use showed that 85.8% of the LOS for all-
cause hospitalization and 82.9% of inpatient stays were
attributed to SCD-related diagnoses. These results are
similar to those from other studies that have analyzed
SCD-related health care utilization, in which SCD
patients were observed to have had an average of 3.7
inpatient hospitalizations and 24.1 hospital days, with
roughly 84% attributable to SCD-related diagnoses dur-
ing the study period [16]. Also, SCD patients incurred
higher costs (76.6% of total health care cost attributed to
SCD-related diagnoses). The results are again similar to
the study by Kauf et al. that found 64% of costs were
SCD-related [16]. HU adherence among SCD patients
has also been associated with decreased risk of SCD-
related hospitalization, all-cause and SCD-related ER
visits, and vaso-occlusive events [32, 42]. In addition, the
difference in all-cause health care resource utilization in
the baseline and follow-up periods showed a decrease in
all-cause hospitalization, inpatient LOS, and outpatient
ER visits. The decrease may have been due to the reduc-
tion in severe SCD-related complications that would
Fig. 7 All cause and SCD-related health care costs. SCD: sickle cell disease; ER: emergency room
Shah et al. Health and Quality of Life Outcomes          (2019) 17:155 Page 8 of 11
warrant ER and inpatient visits, or longer hospitaliza-
tions possibly resulting from HU utilization during the
follow-up period.
Few studies have examined the proportion of SCD
patients who are prescribed HU as well as pain medica-
tion. Our study found that almost half of the patients
were prescribed opioids (49.0%) and nonsteroidal anti-
inflammatory drugs (NSAIDs) (55.5%) during the follow-
up period. Another study showed that older age, HU
therapy, NSAID use, and frequent inpatient hospitaliza-
tions were associated with high-dose opioid use [43].
The high rate of pain medication utilization in this
population of SCD patients may be because these SCD
patients have a higher tendency to use pain medication
because of high disease morbidity. Recommendations for
HU use include SCD patients with ≥3 moderate to se-
vere pain episodes within a 12-month period [22, 44,
45]. This study also observed a low rate of indications
for pneumococcal and meningococcal vaccines during
the 12-month follow-up period (4.4 and 2.9%,
respectively).
The abovementioned results on treatment patterns for
vaccines are limited in that they may not have captured
the true rate of SCD patients prescribed HU who were
also administered these vaccines, since they are not
given annually. It is possible that most patients received
the recommended vaccine prior to the 12-month follow-
up period, or their next vaccine dose may have occurred
outside the study’s 12-month follow-up period [46].
More generally, certain other limitations are associated
with the use of any claims data, which are collected for
the purpose of payment and not research. While medi-
cation adherence was measured using MPR, which is a
widely accepted method for measurement in observa-
tional studies, the presence of a claim for a filled pre-
scription does not indicate whether the medication was
taken as prescribed or at all. Moreover, medications
filled over-the-counter or provided as samples by the
physician are not observed in claims data. In addition,
the presence of a diagnosis code on a medical claim does
not indicate a positive presence of disease, as the diagno-
sis code may be incorrectly coded or included as rule-
out criteria rather than actual disease. Finally, claims
data cannot capture certain demographic and clinical
parameters.
For this study, results related to medication use and
HU treatment patterns, among other results, may not be
generalizable to other populations. The study setting is
within the Medicaid population that consists of patients
with disabilities, children of low-income families, preg-
nant women, parents of Medicaid-eligible children who
meet certain income requirements, and low-income
seniors [47]. These populations are more likely to have
unmet needs in health care resource services. Individuals
with dual eligibility for both Medicaid and Medicare
were excluded, since data for these observations are not
complete; together with the likelihood that many pa-
tients switched entirely from Medicaid to Medicare at
age 65, this exclusion may have resulted in underrepre-
sentation of patients aged 65 years or older, and there-
fore further limits the generalizability of the results to
broader populations. Additionally, due to the limited
availability of the data, the data of managed care plan
patients only includes 14 states, and the study period
until December 2013 was the most recent data at the
time of study. SCD management guidelines have
remained consistent in the past decade, so the findings
of this study should remain valid in the current year.
Furthermore, health care utilizations and costs can only
be identified among patients enrolled in an FFS health
plan. Therefore, the actual health care costs may be
higher or lower than reported here, which may limit the
ability of cost outcomes to be generalized to the entire
Medicaid SCD population.
Finally, it is important to note that the present study
was limited in scope to general associations between
treatments and economic outcomes, and does not in-
clude certain parameters that may affect outcomes, such
as associations between compliance and age and comor-
bidities, clinical guidelines, and certain clinical parame-
ters that fell out of scope; nonetheless, the findings
underscore the need for future investigation of more
specific research questions.
Conclusions
Despite the positive disease-modifying effects of HU ther-
apy, SCD patients treated with HU continue to have sig-
nificant unmet needs in terms of medication adherence,
high rates of treatment discontinuation, and high eco-
nomic burden. Future research is needed to evaluate the
reasons for discontinuation in a real-world data popula-
tion, and to develop disease management strategies to
help alleviate the SCD-related health care burden.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12955-019-1225-7.
Additional file 1: Table S1. Sensitivity Analysis for Discontinuation
Using 30- and 60-Day Refill Gaps.
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